ABBV AbbVie Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
23:58
Jul 15
Jul 15
Buy AbbVie, fantastic performance
AbbVie is performing fabulously, not just a spin-off, and should be bought.
MED
22:58
Jul 13
Jul 13
Hold ABBV as a defensive healthcare rotation play entered from the lows; author is rotating into non-tech sectors during an expected ~70-day late-cycle rotation away from technology.
MED
01:49
Jul 08
Jul 08
Named as a likely acquirer of ERAS; merger docs from APGE deal show AbbVie sought expedited timeline to free BD bandwidth for additional deals.
MED
01:21
Jul 03
Jul 03
Author describes a balanced core portfolio rebalanced in June 2026 that has outperformed the S&P 500, but the tweet is a retrospective performance update and general advice to stay balanced, not a fresh trade call.
23:56
Jul 02
Jul 02
The author analyzes merger document details between AbbVie and Apogee, noting AbbVie's ultimatum and competitive interest in the AtD space, but does not state a personal position or forward call.
LOW
23:24
Jul 02
Jul 02
The tweet details the merger timeline between AbbVie and Apogee with no author position, noting that the atopic dermatitis space remains of interest to biopharma.
LOW
15:54
Jul 02
Jul 02
Long these names as part of a balanced portfolio rebalanced on 6/15 to rotate out of tech into healthcare, financials, energy, and defensives, outperforming SPY by 4x.
MED
14:00
Jul 01
Jul 01
Reports Goldman Sachs increasing position in $ABBV as part of hedging with healthcare.
MED
06:06
Jul 01
Jul 01
US lawmakers have launched an investigation into the China drug trial activities of Merck & Co. and AbbVie.
13:38
Jun 30
Jun 30
U.S. House committee investigates AbbVie and Merck over China drug trials to determine if they fueled China's military capabilities
11:33
Jun 30
Jun 30
Pre-market movers include Apple and Google flat on UK CMA probe, CNXC plunging 24% on weak outlook, DLR falling 5% on data center deal, AVAV surging 28% on earnings beat, GMAB rising 8% on positive trial results, ABBV and MRK dipping on House investigation, and LCII up 7% on merger with Patrick Industries.
02:20
Jun 26
Jun 26
Author holds ABBV as a current portfolio position across both healthcare and biotech allocations, part of a defensive balance strategy ahead of expected 3-month market chop.
MED
09:07
Jun 23
Jun 23
AbbVie receives European Union approval for its hepatitis C treatment Mavyret.
23:45
Jun 22
Jun 22
AbbVie acquires Apogee to bolster its immunology pipeline with a potential Dupixent rival.
LOW
17:33
Jun 22
Jun 22
Apogee deal expands AbbVie's inflammation pipeline.
AbbVie's acquisition of Apogee Therapeutics adds a promising late-stage eczema treatment to its dominant inflammation franchise, alongside existing blockbusters with tens of billions in forecast sales, strengthening its long-term growth.
MED
14:15
Jun 22
Jun 22
Apogee deal boosts AbbVie's dermatology pipeline.
AbbVie's acquisition of Apogee Therapeutics adds a pipeline drug for atopic dermatitis (eczema) with convenient every-3-to-6-month dosing, enhancing patient compliance. This strengthens AbbVie's already dominant immunology franchise (Skyrizi, Rinvoq) forecast to generate $50-60 billion in revenue, extending growth beyond 2030 and reinforcing its competitive position against Sanofi's Dupixent.
MED
12:46
Jun 22
Jun 22
ABBV announces post‑acquisition financial flexibility; factual statement from company, no directional view from speaker.
LOW
11:53
Jun 22
Jun 22
The author declares OX40 target dead and questions SNY's Amlitelimab continuation, but provides no personal position or forward trade call.
LOW
11:43
Jun 22
Jun 22
AbbVie announces agreement to acquire Apogee Therapeutics for 135 dollars 11 cents per share in cash to deepen its immunology pipeline.
11:25
Jun 22
Jun 22
AbbVie agreed to acquire Apogee Therapeutics for 10.9 billion dollars to strengthen its anti-inflammatory drug portfolio amid rising competition for its top-selling product.
11:01
Jun 22
Jun 22
AbbVie agrees to acquire Apogee Therapeutics for $135.11 per share in an all-cash deal.
11:00
Jun 22
Jun 22
Reports ABBV to acquire APGE for $135.11/share cash; no directional view from speaker.
MED
16:15
Jun 20
Jun 20
Author alleges ABBV is structurally exploiting PBM/insurer incentives to block biosimilar competition and sustain high-priced branded drug revenues — moral criticism, no personal trading position stated.
MED
15:35
Jun 20
Jun 20
The author questions who would buy ORKA or SYRE given ABBV's extended half-life IL-23, implying competitive risk but without a clear position or forward call.
LOW
23:40
Jun 19
Jun 19
Reports AbbVie as acquirer in $11bn deal for Apogee Therapeutics; factual M&A announcement, speaker expresses no opinion.
MED
15:48
Jun 19
Jun 19
Author describes ABBV's strategic bet on US payer system inefficiency, but does not state a personal directional view.
LOW
15:15
Jun 19
Jun 19
The author notes that most industry contacts viewed AbbVie as the least likely acquirer among pharma companies with IBD franchises, especially after public criticism of the drug.
LOW
14:57
Jun 19
Jun 19
AbbVie is nearing an $11 billion cash deal to acquire Apogee Therapeutics to strengthen its anti-inflammatory drug portfolio, per a Financial Times report.
14:52
Jun 19
Jun 19
The tweet suggests plane tracking alpha exists for AbbVie and Apogee, referencing a quoted context about unusual AbbVie fleet activity near Bozeman that previously preceded a major deal, but the author does not state a position or forward call.
LOW
14:34
Jun 19
Jun 19
Author reviews merger documents and identifies read-through targets for potential takeovers, but does not state personal positions or forward calls.
LOW
About ABBV Analyst Coverage
Buzzberg tracks ABBV (AbbVie Inc.) across 16 sources. 11 bullish vs 0 bearish calls from 18 analysts. Sentiment: predominantly bullish (20%). 55 total trade ideas tracked. Past 7 days: 2 bullish. Latest voices: Jim Cramer, asklivermore, seedy19tron.